<DOC>
	<DOCNO>NCT00002349</DOCNO>
	<brief_summary>To compare antiviral effect stavudine ( d4T ) versus placebo patient evidence recent HIV infection . Also , compare immunologic effect effect quality life d4T patient .</brief_summary>
	<brief_title>A Pilot Study Compare Antiviral Immunologic Effects Stavudine ( d4T ) Versus Placebo Subjects With Evidence Recent HIV Infection .</brief_title>
	<detailed_description>Patients receive d4T placebo every 12 hour 4 week , dose decrease ( placebo ) every 12 hour . Treatment continue least 48 week .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Inclusion Criteria Patients must : Recent HIV infection . No prior antiretroviral therapy . No acute opportunistic infection study entry . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Intractable diarrhea . Bilateral peripheral neuropathy . Any condition would preclude study therapy . Concurrent Medication : Excluded : Myelosuppressive , neurotoxic , hepatotoxic drug . Patients follow prior condition exclude : History bilateral peripheral neuropathy . Prior Medication : Excluded : Prior antiretroviral therapy . Myelosuppressive , neurotoxic , cytotoxic agent within 3 month prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Stavudine</keyword>
</DOC>